Ocular TRUT: Nationwide Antimicrobial uceptibility Pattern in Ocular Iolate Original Reearch Article

Purpoe Ocular Tracking Reitance in U.. Today (TRUT) annually evaluate in vitro antimicrobial uceptibility of taphylococcu aureu, treptococcu pneumoniae, and Haemophilu influenzae to ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, penicillin, azithromycin, tobramycin, trimethoprim, and polymyxin B in national ample of ocular iolate. Deign Laboratory invetigation. Method Propectively collected ocular iolate (197 . aureu, 49 . pneumoniae, and 32 H. influenzae) from 35 intitution and archived ocular iolate (760 . pneumoniae and 356 H. influenzae) from 34 intitution were teted by an independent, central laboratory. Mean minimum inhibitory concentration that would inhibit growth of 90% of the teted iolate (MIC90) were interpreted a uceptible, intermediate, or reitant according to tandardized breakpoint for ytemic treatment. . aureu iolate were claified a methicillin uceptible (MA) or methicillin reitant (MRA). Reult MA or MRA uceptibility pattern were virtually identical for the fluoroquinolone, that i, MA uceptibility wa 79.9% to 81.1% and MRA uceptibility wa 15.2%. Trimethoprim wa the only agent teted with high activity againt MRA. All . pneumoniae iolate were uceptible to gatifloxacin, levofloxacin, and moxifloxacin; 89.8% were uceptible to ciprofloxacin. H. influenzae iolate were 100% uceptible to all teted agent but trimethoprim. Ocular TRUT 1 data were conitent with the eight-year longitudinal ample of archived ocular iolate. Concluion The fluoroquinolone were conitently active in MA, . pneumoniae, and H. influenzae. After more than a decade of intenive ciprofloxacin and levofloxacin ue a ytemic therapy, 100% of ocular . pneumoniae iolate were uceptible to gatifloxacin, levofloxacin, and moxifloxacin; nonuceptibility to ciprofloxacin wa le than 15%. High-level in vitro MRA reitance ugget the need to conider alternative therapy to fluoroquinolone when MRA i a likely pathogen.